Relationship between insulin resistance and reduction in oxidative stress in vivo by atorvastatin

Journal of Cardiology

Volumn 44, Issue 6, 2004, Pages 233-242

  Hitsumoto, Takashi ^a   Iizuka, Takuo ^a   Takahashi, Mao ^a   Nakamura, Keijirou ^a   Shimizu, Kazuhiro ^a   Satoh, Shin ^a   Sugiyama, Yuko ^a   Sakurai, Takeshi ^a   Noike, Hirofumi ^a   Ohsawa, Hidefumi ^a   Watanabe, Hitoshi ^a   Shirai, Kohji ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Free radicals; Hyperlipoproteinemia; Insulin (resistance); Lipid modifying agents (atorvastatin)

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ATORVASTATIN; BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATINE DERIVATIVE; TRIACYLGLYCEROL; 8 EPI PROSTAGLANDIN F2ALPHA; 8-EPI-PROSTAGLANDIN F2ALPHA; DRUG DERIVATIVE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PROSTAGLANDIN F2 ALPHA; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; INSULIN RESISTANCE; MALE; OXIDATIVE STRESS; PROSTAGLANDIN URINE LEVEL; URINARY EXCRETION; BLOOD; DRUG EFFECT; HOMEOSTASIS; MIDDLE AGED; PATHOPHYSIOLOGY; URINE;

AGED; DINOPROST; FEMALE; HEPTANOIC ACIDS; HOMEOSTASIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PYRROLES;

EID: 13744263778     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB: Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. JAMA 1986; 256: 2835-2838
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389
4. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-1719
5. Maron DJ, Fazio S, Linton MF: Current perspectives on statins. Circulation 2000; 101: 207-213
6. Vaughan CJ, Gotto AM Jr, Basson CT: The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000; 35: 1-10
7. Koh KK: Effects of statins on vascular wall: Vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000; 47: 648-657
8. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rutten H, Fichtlscherer S, Martin H, Zeiher AM: HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001; 108: 391-397
9. Negre-Aminou P, van Vliet AK, van Erck M, van Thiel GC, van Leeuwen RE, Cohen LH: Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors: Comparison with other human cell types. Biochim Biophys Acta 1997; 1345: 259-268
10. Chen H, Ikeda U, Shimpo M, Shimada K: Direct effects of statins on cells primarily involved in atherosclerosis. Hypertens Res 2000; 23: 187-192
11. Sakai M, Kobori S, Matsumura T, Biwa T, Sato Y, Takemura T, Hakamata H, Horiuchi S, Shichiri M: HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein. Atherosclerosis 1997; 133: 51-59
12. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, Shiomi M, Schoen FJ, Libby P: An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001; 103: 276-283
13. Fontaine D, Otto A, Fontaine J, Berkenboom G: Prevention of nitrate tolerance by long-term treatment with statins. Cardiovasc Drugs Ther 2003; 17: 123-128
14. Inoue T, Takayanagi K, Hayashi T, Morooka S: Fluvastatin attenuates nitrate tolerance in patients with ischemic heart disease complicating hypercholesterolemia. Int J Cardiol 2003; 90: 181-188
15. Matsumoto K, Kizaki Y, Fukae S, Tomihira M, Sera Y, Ueki Y, Tominaga T, Miyake S: Insulin resistance and coronary risk factors in Japanese type 2 diabetic patients with definite coronary artery disease. Diabetes Res Clin Pract 2001; 51: 181-186
16. Kobayashi H, Nakamura T, Miyaoka K, Nishida M, Funahashi T, Yamashita S, Matsuzawa Y: Visceral fat accumulation contributes to insulin resistance, small-sized low-density lipoprotein, and progression of coronary artery disease in middle-aged non-obese Japanese men. Jpn Circ J 2001; 65: 193-199
17. Hitsumoto T, Yoshinaga K, Sakurai T, Aoyagi K, Matsumoto J, Iizuka T, Kaku M, Sugiyama Y, Kanai M, Uchi T, Noike H, Ohsawa H, Watanabe H, Shirai K: Clinical significance of preheparin serum lipoprotein lipase mass in normocholesterolemic patients with coronary artery disease. J Cardiol 2002; 40: 1-9 (in Jpn with Eng abstr)
18. 2-imbalance in insulin-resistant rat aorta. Diabetes 1999; 48: 2437-2445
19. Kashiwagi A, Shinozaki K, Nishio Y, Okamura T, Toda N, Kikkawa R: Free radical production in endothelial cells as a pathogenetic factor for vascular dysfunction in the insulin resistance state. Diabetes Res Clin Pract 1999; 45: 199-203
20. Hitsumoto T, Iizuka T, Takahashi M, Yoshinaga K, Matsumoto J, Shimizu K, Kaku M, Sugiyama Y, Sakurai T, Aoyagi K, Kanai M, Noike H, Ohsawa H, Watanabe H, Shirai K: Relationship between insulin resistance and oxidative stress in vivo. J Cardiol 2003; 42: 119-127(in Jpn with Eng abstr)
21. Paolisso G, Barbagallo M, Petrella G, Ragno E, Barbieri M, Giordano M, Varricchio M: Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 2000; 150: 121-127
22. Mangaloglu L, Cheung RC, Van Iderstine SC, Taghibiglou C, Pontrelli L, Adeli K: Treatment with atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: Evidence that reduced hypertriglyceridemia is accompanied by improved hepatic insulin sensitivity. Metabolism 2002; 51: 409-418
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
24. Oimatsu H, Saitoh S, Ura N, Shimamoto K: A practical index for evaluation of insulin resistance. J Japan Diab Soc 2000; 43: 205-213 (in Jpn with Eng abstr)
25. DeFronzo RA: Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: A balanced overview. Diabetologia 1992; 35: 389-397
26. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
27. Reilly M, Delanty N, Lawson JA, FitzGerald GA: Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 1996; 94: 19-25
28. Reilly MP, Pratico D, Delanty N, DiMinno G, Tremoli E, Rader D, Kapoor S, Rokach J, Lawson J, FitzGerard GA: Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation 1998; 98: 2822-2828
29. Pratico D, Iuliano L, Mauriello A, Spagnoli L, Lawson JA, Rokach J, Maclouf J, Violi F, FitzGerald GA: Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest 1997; 100: 2028-2034
30. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148
31. Azumi H, Inoue N, Takeshita S, Rikitake Y, Kawashima S, Hayashi Y, Itoh H, Yokoyama M: Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation 1999; 100: 1494-1498
32. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501
33. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, Linz W, Bohm M, Nickenig G: Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22: 300-305
34. Christ M, Bauersachs J, Liebetrau C, Heck M, Gunther A, Wehling M: Glucose increases endothelial-dependent superoxide formation in coronary arteries by NAD(P)H oxidase activation: Attenuation by the 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor atorvastatin. Diabetes 2002; 51: 2648-2652
35. Kashiwagi A, Shinozaki K, Nishio Y, Maegawa H, Maeno Y, Kanazawa A, Kojima H, Haneda M, Hidaka H, Yasuda H, Kikkawa R: Endothelium-specific activation of NAD (P)H oxidase in aortas of exogenously hyperinsulinemic rats. Am J Physiol 1999; 277: E976-E983
36. Malik J, Melenovsky V, Wichterle D, Haas T, Simek J, Ceska R, Hradec J: Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial - FAT). Cardiovasc Res 2001; 52: 290-298
37. Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG: Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003; 52: 803-811
38. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS, for the Atorvastatin versus Revascularization Treatment Investigators: Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Eng J Med 1999; 341: 70-76
39. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001; 285: 1711-1718
40. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG: Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention: The GREek Atorvastatin and Cororary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18: 220-228
41. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158
42. Reaven GM: Banting lecture 1988: Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607
43. Kaplan NM: The deadly quartet: Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149: 1514-1520
44. Ishibashi S, Yamada N, Shimano H, Mori N, Mokuno H, Gotohda T, Kawakami M, Murase T, Takaku F: Apolipoprotein E and lipoprotein lipase serected from human monocyte-derived macrophages modulate very low density lipoprotein uptake. J Biol Chem 1990; 265: 3040-3047
45. Funada J, Sekiya M, Hamada M, Hiwada K: Postprandial elevation of remnant lipoprotein leads to endothelial dysfunction. Circ J 2002; 66: 127-132
46. Inoue T, Uchida T, Kamishirado H, Sakuma M, Sakai Y, Takayanagi K, Hayashi T, Morooka S: Possible relationship between insulin resistance and remnant-like lipoprotein particles in coronary endothelial dysfunction. Clin Cardiol 2002; 25: 532-536
47. Doi H, Kugiyama K, Oka H, Sugiyama S Ogata N, Koide SI, Nakamura SI, Yasue H: Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation 2000; 102: 670-676
48. Jones P, Kafonek S, Laurora I, Hunninghake D: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81: 582-587